Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Tyr1250 - HER2 (rat)

Site Information
PTAENPEyLGLDVPV   SwissProt Entrez-Gene
Predicted information:  Scansite
Orthologous residues: HER2 (human): Y1248, HER2 (mouse): Y1249, HER2 iso5 (human): (Y1218), HER2 iso2 (human): (Y638)
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447614

In vivo Characterization
Methods used to characterize site in vivo: flow cytometry (2), immunoprecipitation (1), microscopy-colocalization with upstream kinase (8), mutation of modification site (2, 7, 8, 10), phospho-antibody (1, 2, 3, 4, 5, 6, 9), western blotting (1, 2, 3, 4, 8)
Disease tissue studied: breast cancer (2, 8), diabetes mellitus (1)
Relevant cell line - cell type - tissue: 'muscle, smooth'-thoracic aorta (6), 3T3 (fibroblast) (10), cholangiocyte (5), COS (fibroblast) (8), G8/DHFR (fibroblast) (9), heart (3), MCF-10A (breast cell) (2), MCF-7 (breast cell) (8), MDCK (epithelial) (2), Rat1 (fibroblast) (7), Schwann (4, 9), vascular (1), VSMC (1)

Controlled by
Putative upstream kinases: HER2 (rat) (2)
Treatments: AG825 (1, 4), AP1510 (2), betacellulin (6), diabetes (1), EGF (8), heart failure (3), laminin-1 (4), nerve_damage (9), neuregulin (3, 4), phorbol_ester (9)

Downstream Regulation
Effects of modification on HER2: molecular association, regulation (6, 8)
Effects of modification on biological processes: cell growth, altered (10)
Induce interaction with: Chk1 (rat) (8), EGFR (rat) (6)

Disease / Diagnostics Relevance
Relevant diseases: breast cancer (8)



Akhtar S, et al. (2013) Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction. PLoS One 8, e67813
23826343   Curated Info


Lucs AV, Muller WJ, Muthuswamy SK (2010) Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene 29, 174-87
19826412   Curated Info


Doggen K, et al. (2009) Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. J Mol Cell Cardiol 46, 33-8
19010331   Curated Info


Thaxton C, Lopera J, Bott M, Fernandez-Valle C (2008) Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 27, 2705-15
17998937   Curated Info


Lai GH, et al. (2005) erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129, 2047-57
16344070   Curated Info


Mifune M, et al. (2004) Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. Am J Physiol Cell Physiol 287, C807-13
15163624   Curated Info


Dankort D, et al. (2001) Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. J Biol Chem 276, 38921-8
11500516   Curated Info


Zrihan-Licht S, et al. (1998) Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation. J Biol Chem 273, 4065-72
9461599   Curated Info


Kwon YK, et al. (1997) Activation of ErbB2 during wallerian degeneration of sciatic nerve. J Neurosci 17, 8293-9
9334404   Curated Info


Mikami Y, et al. (1992) Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. Proc Natl Acad Sci U S A 89, 7335-9
1354355   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.